Synoptic reporting of echocardiography in carcinoid heart disease (ENETS Carcinoid Heart Disease Task Force)
- PMID: 34825753
- PMCID: PMC9286034
- DOI: 10.1111/jne.13060
Synoptic reporting of echocardiography in carcinoid heart disease (ENETS Carcinoid Heart Disease Task Force)
Abstract
Background: This European Neuroendocrine Tumor Society (ENETS) Expert Consensus document aims to provide practical guidance and standardization for echocardiography in the screening and follow-up of carcinoid heart disease (CHD) in patients with a neuroendocrine tumour (NET) and carcinoid syndrome.
Methods: NET experts within the ENETS Carcinoid Heart Disease Task Force reviewed both general reporting guidelines and specialized scoring systems for transthoracic echocardiography (TTE) in CHD. Based on this review, a dedicated template report was designed by the multidisciplinary working group of cardiologists, oncologists, endocrinologists, gastroenterologists, surgeons and radiologists.
Results: We propose a Synoptic Reporting of Echocardiography in Carcinoid Heart Disease which represents an agreed peer reviewed proforma to capture information at the time of referral and enable a detailed outcome of CHD assessment. This includes a systematic and detailed list of structures to evaluate data to capture at the time of reporting of TTE.
Conclusions: Adherence to these reporting guidelines aims to promote homogeneous and detailed evaluation of CHD to secure accurate assessment and allow comparison of studies performed intra- and inter-individually. These guidelines could also facilitate CHD assessment as part of prospective clinical trials to enable standardization of the findings seen in response to therapy.
Keywords: carcinoid heart disease; echocardiography; neuroendocrine neoplasia; synoptic reporting.
© 2021 The Authors. Journal of Neuroendocrinology published by John Wiley & Sons Ltd on behalf of British Society for Neuroendocrinology.
Conflict of interest statement
Dr Johannes Hofland reports speaker honoraria from Ipsen and advisory honoraria from Ipsen and Novartis. Dr Angela Lamarca reports travel and educational support from Ipsen, Pfizer, Bayer, AAA, SirtEx, Novartis, Mylan and Delcath; speaker honoraria from Merck, Pfizer, Ipsen, Incyte, AAA and QED; advisory honoraria from EISAI, Nutricia Ipsen, QED and Roche; and is a member of the Knowledge Network and NETConnect Initiatives funded by Ipsen. Dr Simona Grozinsky‐Glasberg reports speaker and advisory board honoraria from Ipsen and Triple A and has received research grant support from Ipsen and Novartis. Dr Christos Toumpanakis reports speaker and advisory board honoraria from Novartis, IPSEN, AAA and Lexicon and has received education grants for the NET Unit from Novartis, IPSEN, AAA and Lexicon. The other authors declare that they have no conflicts of interest.
References
-
- Thorson A, Biorck G, Bjorkman G, Waldenstrom J. Malignant carcinoid of the small intestine with metastases to the liver, valvular disease of the right side of the heart (pulmonary stenosis and tricuspid regurgitation without septal defects), peripheral vasomotor symptoms, bronchoconstriction, and an unusual type of cyanosis; a clinical and pathologic syndrome. Am Heart J. 1954;47(5):795‐817. - PubMed
-
- Isler P, Hedinger C. Metastatic carcinoid of the small intestine with severe valvular defects especially in the right part of the heart and with pulmonary stenosis; a peculiar symptom complex. Schweiz Med Wochenschr. 1953;83(1):4‐7. - PubMed
-
- Davar J, Connolly HM, Caplin ME, et al. Diagnosing and Managing Carcinoid Heart Disease in Patients With Neuroendocrine Tumors: An Expert Statement. J Am Coll Cardiol. 2017;69(10):1288‐1304. - PubMed
-
- Rorstad O. Prognostic indicators for carcinoid neuroendocrine tumors of the gastrointestinal tract. J Surg Oncol. 2005;89(3):151‐160. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources